Indeed, this stock is news driven, and in the absence of such catalysts the stock tends to drift with the market, perhaps with a downward bias. However, in the next six months there should be enough positive catalysts to keep the stock price up and most likely a gradual increase in the price should be evident as we approach the final outcome on Rida/sarcoma in about six months. I look forward to the company announcing a partnership for 534 which I believe is necessary and will be viewed very favorably by the investment community. I agree with others that 534 is the real prize here, but I am very optimistic that Rida will be approved as there is nothing else out there for sarcoma at this point and any reasonable performance should be enough to compel an approval by the FDA. Should be an interesting six months ahead. Again, glad to be here, away from the "noise" as Don termed it, I believe, on the yahooligan board.
News 
Market Data 
Discover 
